基于RCBTB1临床表达特征的益气化瘀解毒方抑制胃癌肝转移机制研究

Study on the Mechanism of Yiqi Huayu Jiedu Formula in Inhibiting Liver Metastasis of Gastric Cancer Based on Clinical Expression Characteristics of RCBTB1

  • 摘要:
    目的 探讨鸟嘌呤核苷酸交换因子(RCBTB1)在胃癌中的差异表达和诊断预后预测的临床价值,研究益气化瘀解毒方抑制肿瘤相关成纤维细胞分泌的外泌体(CAFs-exo)诱导的胃癌肝转移的作用机制。
    方法 生物信息学结合免疫组化验证RCBTB1在胃癌组织中的表达及诊断预后意义;通过超速离心法分离、提取CAFs-exo,利用透射电镜、Western blot、纳米颗粒跟踪分析(NTA)检测以鉴定;采用划痕、Transwell实验检测细胞侵袭迁移能力;构建胃癌荷瘤小鼠肝转移模型并用益气化瘀解毒方干预,检测肝转移瘤数量,苏木精-伊红(HE)染色检测肝脏中胃癌细胞浸润;Western blot检测相关分子表达;免疫荧光检测胃癌细胞对外泌体的摄取;活体成像观察外泌体在胃癌肝转移小鼠肝脏中的分布。
    结果 RCBTB1在胃癌组织中表达升高(P < 0.001),且具有较高的诊断预测价值(AUC=0.857),其相关差异基因功能主要富集在细胞外基质调节、侵袭转移、细胞黏附等生物学行为以及Wnt/β-catenin信号通路中。RCBTB1在T4期胃癌中的表达量显著高于T2、T3期(P < 0.01),在T2、T3期中,RCBTB1高表达胃癌患者临床预后更好(P < 0.05),而在T4分期中,RCBTB1高表达胃癌患者预后较差(P < 0.05)。益气化瘀解毒方能够显著抑制CAFs-exo诱导的胃癌细胞侵袭迁移能力(P < 0.01)及胃癌荷瘤小鼠肝转移灶形成,上调RCBTB1、E-cadherin(P < 0.001),下调β-catenin、Snail表达(P < 0.001)。同时,益气化瘀解毒方能降低胃癌细胞对外泌体的摄取能力,抑制外泌体在胃癌肝转移模型小鼠的肝脏中聚集。
    结论 RCBTB1在不同分期胃癌中存在差异表达,其在胃癌临床诊断、预后预测中具有重要价值,益气化瘀解毒方能通过阻断CAFs-exo传递并逆转RCBTB1介导的上皮间质转化(EMT)以抑制胃癌肝转移。

     

    Abstract:
    OBJECTIVE To discuss the clinical value of RCBTB1 in the diagnosis and prognosis of gastric cancer (GC), and to study the mechanism of Yiqi Huayu Jiedu Formula (YHJF) underlying suppressing the liver metastasis induced by tumor-associated fibroblasts (CAFs-exo) secreted exosomes.
    METHODS Bioinformatics combined with immunohistochemistry were used to verify the expression of RCBTB1 in GC tissues and its significance in diagnosis and prognosis. CAFs-exo was isolated and extracted by ultrafast centrifugal method, and identified by transmission electron microscopy, Western blot and NTA. The invasion and migration abilities of cells were detected by wound-healing and Transwell assays. The liver metastasis model of mice bearing GC was established, intervened with YHJF, and detected for the number of liver metastases. Hematoxylin-eosin staining was used to detect the infiltration of GC cells in the liver. The expression of related molecules was detected by Western blot. The exosome uptake of GC cells was detected by immunofluorescence. In vivo imaging was performed to observe the distribution of exosomes in the liver of mice with GC liver metastasis.
    RESULTS The expression of RCBTB1 was increased in GC tissues (P < 0.001), and it had high diagnostic and predictive value (AUC=0.857). The related differentially expressed genes of RCBTB1 mainly enriched in biological behaviors such as extracellular matrix regulation, invasion and metastasis, and cell adhesion, as well as the Wnt/β-catenin signaling pathway. The expression level of RCBTB1 in stage T4 GC was significantly higher than that in stage T1, T2 and T3 (P < 0.01). Patients with high expression of RCBTB1 in stage T2 and T3 had a better clinical prognosis (P < 0.05), while those with high expression of RCBTB1 in stage T4 had a poor prognosis (P < 0.05). YHJF could significantly inhibit CAFs-exo induced invasion and migration of GC cells (P < 0.05) and the formation of liver metastases in mice with GC, up-regulate the expression of RCBTB1 and E-cadherin (P < 0.001), and down-regulate the expression of β-catenin and Snail (P < 0.001). Meanwhile, YHJF could reduce the uptake ability of exosomes of GC cells and inhibit the accumulation of exosomes in the liver of mice with GC liver metastasis.
    CONCLUSION RCBTB1 is differentially expressed in GC at different stages and plays an important role in the clinical diagnosis and prognosis prediction of GC. YHJF can prohibit liver metastasis of GC by blocking CAFs-exo transmission and reversing RCBTB1-mediated epithelial mesenchymal transformation.

     

/

返回文章
返回